16th Annual Cardiovascular Update Conference
February 6th and 7th from 8:00 am - 5:00 pm
For details visit: Registration Page

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Editors' Corner | The Ongoing Challenge of Tricuspid Regurgitation
    This month's cover story offers a practical, concise review of contemporary care for patients with tricuspid regurgitation (TR). It synthesizes key lessons from clinical trials that now guide decision-making for direct tricuspid valve interventions.
  • Cover Story | Tricuspid Valve Intervention: Clinical Decision-Making For Patient Selection
    For decades, cardiologists have referred to the tricuspid valve as "the forgotten valve." One reason for this neglect is that tricuspid regurgitation (TR) often goes unnoticed, explains Robert O. Bonow, MD, MACC, Distinguished Professor at Northwestern University Feinberg School of Medicine in Chicago, IL.
  • Feature | Navigating Valve Disease
    Shared decision-making has become central to the management of valve disease, including tricuspid regurgitation (TR) (see cover story) and severe aortic stenosis (AS). If done correctly, it can help clinicians engage patients and families in meaningful discussions about symptoms, prognosis, treatment burden and personal goals...
  • Feature | Cardiovascular Device Safety Can't End at Implantation
    Modern cardiovascular care is dependent on safe and effective implanted devices. In the U.S., the cardiovascular care team implants between one and two million new devices each year. The cumulative total of implanted devices in our patients cannot be accurately estimated but is easily in the tens of millions.
  • Focus on Heart Failure | Beyond Steroidal MRAs: Rethinking MR Blockade in HF
    Mineralocorticoid receptor antagonists (MRAs) are foundational in heart failure with reduced ejection fraction (HFrEF). In patients with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), however, the evidence has been inconsistent and does not build a compelling case for the use of steroidal MRAs in HFpEF/HFmrEF.